Literature DB >> 21837689

The evolution of heart gene delivery vectors.

Nalinda B Wasala1, Jin-Hong Shin, Dongsheng Duan.   

Abstract

Gene therapy holds promise for treating numerous heart diseases. A key premise for the success of cardiac gene therapy is the development of powerful gene transfer vehicles that can achieve highly efficient and persistent gene transfer specifically in the heart. Other features of an ideal vector include negligible toxicity, minimal immunogenicity and easy manufacturing. Rapid progress in the fields of molecular biology and virology has offered great opportunities to engineer various genetic materials for heart gene delivery. Several nonviral vectors (e.g. naked plasmids, plasmid lipid/polymer complexes and oligonucleotides) have been tested. Commonly used viral vectors include lentivirus, adenovirus and adeno-associated virus. Among these, adeno-associated virus has shown many attractive features for pre-clinical experimentation in animal models of heart diseases. We review the history and evolution of these vectors for heart gene transfer.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21837689      PMCID: PMC3292875          DOI: 10.1002/jgm.1600

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  73 in total

1.  Gene delivery to the myocardium by intrapericardial injection.

Authors:  Y Fromes; A Salmon; X Wang; H Collin; A Rouche; A Hagège; K Schwartz; M Y Fiszman
Journal:  Gene Ther       Date:  1999-04       Impact factor: 5.250

2.  ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES.

Authors:  R W ATCHISON; B C CASTO; W M HAMMON
Journal:  Science       Date:  1965-08-13       Impact factor: 47.728

3.  High-efficiency, long-term cardiac expression of foreign genes in living mouse embryos and neonates.

Authors:  G Christensen; S Minamisawa; P J Gruber; Y Wang; K R Chien
Journal:  Circulation       Date:  2000-01-18       Impact factor: 29.690

4.  Myocardial gene transfer and long-term expression following intracoronary delivery of adeno-associated virus.

Authors:  Brian K Kaspar; David M Roth; N Chin Lai; Jeffrey D Drumm; Dawn A Erickson; M Dan McKirnan; H Kirk Hammond
Journal:  J Gene Med       Date:  2005-03       Impact factor: 4.565

Review 5.  New recombinant serotypes of AAV vectors.

Authors:  Guangping Gao; Luk H Vandenberghe; James M Wilson
Journal:  Curr Gene Ther       Date:  2005-06       Impact factor: 4.391

6.  Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.

Authors:  J F Symes; D W Losordo; P R Vale; K G Lathi; D D Esakof; M Mayskiy; J M Isner
Journal:  Ann Thorac Surg       Date:  1999-09       Impact factor: 4.330

7.  Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart.

Authors:  Zhong Wang; Tong Zhu; Chunping Qiao; Liqiao Zhou; Bing Wang; Jian Zhang; Chunlian Chen; Juan Li; Xiao Xiao
Journal:  Nat Biotechnol       Date:  2005-02-27       Impact factor: 54.908

8.  Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.

Authors:  T K Rosengart; L Y Lee; S R Patel; P D Kligfield; P M Okin; N R Hackett; O W Isom; R G Crystal
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

9.  Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8.

Authors:  Katsuya Inagaki; Sally Fuess; Theresa A Storm; Gregory A Gibson; Charles F Mctiernan; Mark A Kay; Hiroyuki Nakai
Journal:  Mol Ther       Date:  2006-05-19       Impact factor: 11.454

10.  Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology.

Authors:  Julia Alter; Fang Lou; Adam Rabinowitz; HaiFang Yin; Jeffrey Rosenfeld; Steve D Wilton; Terence A Partridge; Qi Long Lu
Journal:  Nat Med       Date:  2006-01-29       Impact factor: 53.440

View more
  28 in total

Review 1.  Progress in gene therapy of dystrophic heart disease.

Authors:  Y Lai; D Duan
Journal:  Gene Ther       Date:  2012-02-09       Impact factor: 5.250

Review 2.  Percutaneous approaches for efficient cardiac gene delivery.

Authors:  Kiyotake Ishikawa; Jaume Aguero; Charbel Naim; Kenneth Fish; Roger J Hajjar
Journal:  J Cardiovasc Transl Res       Date:  2013-06-08       Impact factor: 4.132

Review 3.  Gene therapy for the prevention of vein graft disease.

Authors:  Kevin W Southerland; Sarah B Frazier; Dawn E Bowles; Carmelo A Milano; Christopher D Kontos
Journal:  Transl Res       Date:  2012-12-27       Impact factor: 7.012

Review 4.  Myocardial gene transfer: routes and devices for regulation of transgene expression by modulation of cellular permeability.

Authors:  Michael G Katz; Anthony S Fargnoli; Charles R Bridges
Journal:  Hum Gene Ther       Date:  2013-04-01       Impact factor: 5.695

5.  Live cell imaging of primary rat neonatal cardiomyocytes following adenoviral and lentiviral transduction using confocal spinning disk microscopy.

Authors:  Takashi Sakurai; Anthony Lanahan; Melissa J Woolls; Na Li; Daniela Tirziu; Masahiro Murakami
Journal:  J Vis Exp       Date:  2014-06-24       Impact factor: 1.355

Review 6.  Cardiac gene therapy: are we there yet?

Authors:  P N Matkar; H Leong-Poi; K K Singh
Journal:  Gene Ther       Date:  2016-04-29       Impact factor: 5.250

7.  AAV-8 is more efficient than AAV-9 in transducing neonatal dog heart.

Authors:  Xiufang Pan; Yongping Yue; Keqing Zhang; Chady H Hakim; Kasun Kodippili; Thomas McDonald; Dongsheng Duan
Journal:  Hum Gene Ther Methods       Date:  2015-04-01       Impact factor: 2.396

8.  Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy.

Authors:  Yongping Yue; Ibrahim M Binalsheikh; Stacey B Leach; Timothy L Domeier; Dongsheng Duan
Journal:  Expert Opin Orphan Drugs       Date:  2015-12-17       Impact factor: 0.694

9.  Opsin spectral sensitivity determines the effectiveness of optogenetic termination of ventricular fibrillation in the human heart: a simulation study.

Authors:  Thomas V Karathanos; Jason D Bayer; Dafang Wang; Patrick M Boyle; Natalia A Trayanova
Journal:  J Physiol       Date:  2016-04-24       Impact factor: 5.182

10.  Long-term robust myocardial transduction of the dog heart from a peripheral vein by adeno-associated virus serotype-8.

Authors:  Xiufang Pan; Yongping Yue; Keqing Zhang; William Lostal; Jin-Hong Shin; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2013-05-09       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.